We are live on ! Find out more
BBOT

BridgeBio Oncology
BBOT

31 hedge funds and large institutions have $167M invested in BridgeBio Oncology in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

7% more funds holding

Funds holding: 29 → 31 (+2)

4.05% more ownership

Funds ownership: 84.98% → 89.02% (+4%)

0% more capital invested

Capital invested by funds: $167M → $167M (+$524K)

Holders
31
Holders Change
+2
Holders Change %
+6.9%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
+$1.83M
2
TD Asset Management
TD Asset Management
Ontario, Canada
+$1.49M
3
Millennium Management
Millennium Management
New York
+$119K
4
Walleye Capital
Walleye Capital
New York
+$6.59K
5
ACM
ADAR1 Capital Management
Texas
+$6.57K

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$180K
2
CAC
Cowen and Company
New York
-$40.2K
3
WP
Woodline Partners
California
-$35.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$29.7M – – –
BlackRock
2
BlackRock
New York
$15.3M – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$14.3M – – –
Citadel Advisors
4
Citadel Advisors
Florida
$13.6M +$566 +55 +0%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$11.6M – – –
Millennium Management
6
Millennium Management
New York
$11.4M +$119K +11,610 +1%
SC
7
Sculptor Capital
New York
$7.21M – – –
FCM
8
Farallon Capital Management
California
$6.13M – – –
CC
9
Commodore Capital
New York
$5.11M – – –
GPP
10
Great Point Partners
Connecticut
$5.11M – – –
PA
11
Perceptive Advisors
New York
$5.11M – – –
SCM
12
Silverarc Capital Management
Massachusetts
$5.11M – – –
SFM
13
Soros Fund Management
New York
$4.85M – – –
ACM
14
ADAR1 Capital Management
Texas
$4.13M +$6.57K +638 +0.2%
T. Rowe Price Investment Management
15
T. Rowe Price Investment Management
Maryland
$4.09M – – –
GTC
16
Ghost Tree Capital
New York
$3.07M – – –
LCM
17
Laurion Capital Management
New York
$3.07M – – –
AAA
18
Affinity Asset Advisors
New York
$2.56M – – –
OCA
19
Octagon Capital Advisors
New York
$2.56M – – –
SC
20
Stempoint Capital
New York
$2.04M – – –
Two Sigma Investments
21
Two Sigma Investments
New York
$1.93M – – –
Wellington Management Group
22
Wellington Management Group
Massachusetts
$1.89M -$180K -17,490 -9%
ACP
23
Acuta Capital Partners
California
$1.82M +$1.83M +177,836 New
TD Asset Management
24
TD Asset Management
Ontario, Canada
$1.48M +$1.49M +144,772 New
WP
25
Woodline Partners
California
$1.06M -$35.6K -3,458 -3%
1
2

BBOT Hedge Fund Activity: Q2 2024 in Review

31 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q2 2024, worth a combined $167M — up 0.31% from $167M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new BBOT positions and 0 closed out — a net gain of 2 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $1.83M. The largest seller was Wellington Management Group, cutting an estimated $180K.

  • 31 institutional investors held BridgeBio Oncology (BBOT) as of Q2 2024, up from 29 in Q1 2024.
  • Funds reported $167M of BridgeBio Oncology stock for Q2 2024, up 0.31% quarter-over-quarter.
  • 2 funds opened new BridgeBio Oncology positions in Q2 2024 and 0 closed out, a net change of +2 holders.
  • The largest BridgeBio Oncology buyer in Q2 2024 was Acuta Capital Partners, an estimated $1.83M added.
  • The largest BridgeBio Oncology seller in Q2 2024 was Wellington Management Group, an estimated $180K sold.

Based on aggregated 13F filings for Q2 2024.